Prevalence of Low Peak Inspiratory Flow Rate (PIFR) in Chronic
Obstructive Pulmonary Disease (COPD) Patients At Discharge After an
Exacerbation – Poster Board #A1506, Board P176; Sunday, May 15, 2016,
11:00 a.m. – 12:45 p.m., at Area B, Hall D (Lower Level), North
Building, Moscone Center.
About COPD
Chronic obstructive pulmonary disease, also known as COPD, includes chronic bronchitis and emphysema, and is a progressive respiratory disease that causes worsening obstruction to airflow in the lungs over time.2 Approximately 15.7 million adults in the U.S. report that they have been diagnosed with COPD.3 It is estimated that several million more adults have undiagnosed COPD.4 COPD is responsible for over 120,000 deaths per year, making it the third leading cause of death in the U.S.3 COPD develops slowly and the symptoms often worsen over time, potentially limiting the ability to perform routine activities.1 Symptoms of COPD include constant coughing, wheezing, shortness of breath, excess production of mucus in the lungs, the inability to breathe deeply and the feeling of being unable to breathe.3
About Brovana® (arformoterol tartrate) Inhalation Solution
Brovana® (arformoterol tartrate) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.
